DelMar Pharmaceuticals (DMPI) shares rallied more than 180% on Friday after the company gave an encouraging update to its first- and second-line mid-stage trials of VAL-083 in patients with MGMT-unmethylated glioblastoma multiforme at the annual ASCO cancer meeting in Chicago.
For the front-line treatment of the drug with radiation therapy, the trial showed eight patients getting a “complete response” and seven patients with “stable disease,” while 14 of the 18 patients enrolled so far were still alive at the data cut-off date. The trial is designed to enroll up to 30 patients.
As a second-line treatment, the study of 47 patients showed 26% with higher dosing got “stable disease” designation and 33% got the same rating with smaller dose. The trial aims to enroll up to 83 patients.
Consistent with prior studies, myelosuppression, primarily thrombocytopenia and neutropenia, is the most common adverse event in both ongoing clinical trials, the firm said.